Introduction {#Sec1}
============

Stress hyperglycemia and insulin resistance are frequent in critically ill patients and associated with poor outcome \[[@CR1],[@CR2]\]. As compared with permissive hyperglycemia, intensive insulin therapy targeting a tight low range for blood glucose has been shown to reduce in-hospital mortality in a single-center randomized trial in critically ill surgical patients \[[@CR3]\]. However, subsequent multicenter randomized controlled trials in broader intensive care unit (ICU) populations either did not find a survival benefit \[[@CR4]-[@CR7]\] or suggested increased mortality \[[@CR8]\]. In these studies, a higher prevalence of hypoglycemia was associated with intensive insulin therapy. In patients with diabetes, hypoglycemia is widely recognized as a severe adverse event, leading to neurological insult or death \[[@CR9],[@CR10]\]. Such association is less clear in the ICU because, in some trials, researchers who have assessed tight blood glucose control observed an increase in hypoglycemia occurrence with \[[@CR11],[@CR12]\] or without \[[@CR4]-[@CR7]\] a significant increase in mortality. There is a clear association between severity of ICU patients and the occurrence of hypoglycemia \[[@CR13]\], and this association may often be underestimated when analyzing the possible link between hypoglycemia and mortality. Moreover, previous studies were associated with methodological concerns, as they included events as covariates that may have been due to hypoglycemia \[[@CR11],[@CR14]\] or because multivariate analyses may be subject to overfitting due to the multiplicity of cofounders included in the model \[[@CR15]-[@CR17]\]. Therefore, the link between hypoglycemia and mortality, as well as its causality, remains a matter of debate \[[@CR18]\].

We used the large cohort of ICU patients included in our recent randomized study \[[@CR7]\] to test the hypothesis that hypoglycemia is associated with a poor outcome, even when controlling for initial severity. For this purpose, we used a multivariate analysis taking into account only variables observed at admission. We also used a multivariate matching process, which is less sensitive to unknown bias variables and is considered more powerful, approaching the ideal randomization that is not possible here \[[@CR19]\]. We also tested the two other main components of glycemic control (mean blood glucose level and blood glucose variability) that are also suspected to be linked to mortality in ICU patients \[[@CR20]\].

Material and methods {#Sec2}
====================

This is an ancillary study of the Computerized Glucose Control in Critically Ill Patients (CGAO-REA) trial (NCT01002482, registered 26 Oct 2009), a non-blinded parallel-group randomized controlled trial involving adult patients admitted to ICUs and comparing tight glucose control with a clinical computerized decision-support systems (blood glucose range between 4.4 and 6.1 mmol/L) and conventional glucose control protocols (blood glucose levels inferior to 10 mmol/L), \[[@CR7]\] and corresponds to a post hoc analysis. A subgroup analysis of patients with traumatic brain injury has also been published \[[@CR21]\]. The study was approved by an ethical committee (Comité de Protection des Personnes, CCP de Tours, Tours, France). Written informed consent or delayed consent was obtained from each patient or a legal surrogate.

Patients {#Sec3}
--------

Adult patients who were assumed to require at least 3 days in the ICU were eligible for inclusion. We excluded moribund patients with imminent death or those for whom there were do-not-resuscitate orders or the attending physicians were not committed to full supportive care, patients admitted for treatment of diabetic ketoacidosis or hyperosmolar state, patients expected to be eating before the end of the day following the day of admission in the ICU, patients who had previously suffered hypoglycemia without documented full neurological recovery, and patients considered as being at high risk of suffering hypoglycemia. It was not mandatory that the patient experienced an episode of hyperglycemia within 24 hours after admission.

Study design {#Sec4}
------------

Within 24 hours after admission, patients were randomly assigned to undergo tight computerized glucose control or conventional blood glucose control \[[@CR7]\]. Blood samples for glucose measurement were obtained by means of arterial catheters whenever possible; the use of capillary samples was discouraged. Blood glucose was measured with bedside glucose readers or preferentially with arterial blood gas analyzer devices when available. At least one blood glucose value per day was measured by the hospital central laboratory on a morning sample (morning laboratory blood glucose). Only the blood glucose values measured at the bedside (for example, either with point-of-care glucose readers or with blood gas analyzers located in the ICU) were used uncorrected for the adaptation of insulin infusion rate. Each ICU used regular human insulin in saline with the same concentration (50 IU in 50 ml of 0.9% sodium chloride) with the use of a pump. A dedicated line for intravenous insulin infusion was encouraged to avoid occult administration of insulin or delay for effective application of a new insulin rate. Enteral feeding was attempted as early as possible. All other aspects of patient care, including nutritional management, were carried out at the discretion of the treating physicians.

At baseline, clinical characteristics, including the Simplified Acute Physiology Score (SAPS II) \[[@CR22]\], presence of trauma, the McCabe score for the evaluation of the prognosis of the underlying disease \[[@CR23]\] and the Sequential Organ Failure Assessment (SOFA) score \[[@CR24]\] were collected.

Definition of hypoglycemia and blood glucose metrics {#Sec5}
----------------------------------------------------

Blood glucose control was assessed by morning laboratory blood glucose each day until ICU discharge or day 28. Because different numbers of measures per day were obtained in the two groups, we extracted only four blood glucose measurements per day, closest to 2:00, 8:00, 14:00, and 20:00, respectively. Severe hypoglycemia was defined as blood glucose \<2.2 mmol/L, and moderate hypoglycemia was defined as blood glucose between 2.2 and 3.3 mmol/L, as previously described \[[@CR7]\]. The number of hypoglycemic events was recorded in each patient, and the density was calculated (expressed as number of events per day of insulin administration and per day in the ICU). We also recorded the mean, minimal and maximal blood glucose readings during the intervention period, the standard deviation (SD) and coefficient of variation (CV) of blood glucose, and the total and daily doses of insulin. Blood glucose variability was considered as moderate (CV, 0.20 to 0.39) or severe (CV, \>0.40) as previously described \[[@CR16]\].

Outcome measures {#Sec6}
----------------

The study primary outcome was death due to any cause within 90 days after ICU admission. Secondary predefined outcomes were death within 28 days after ICU admission, 28-day ICU-free days, 28-day hospital-free days, 28-day ventilator-free days (either mechanical ventilation or non-invasive ventilation), 28-day free-of-catecholamines days, and 28-day free of renal replacement therapy, as previously described \[[@CR7],[@CR25]\]. These 28-day free-of-treatment days were calculated by subtracting the actual treatment duration in days from 28, with patients who died at day 28 or before being assigned 0 free days. We also compared the following main glucose metrics: mean blood glucose and blood glucose CV \[[@CR20]\].

Statistical analysis {#Sec7}
--------------------

Data are expressed as mean ± SD, median (25th to 75th interquartile range) and number (percentage). Normality was assessed with the D'Agostino-Pearson omnibus test. Comparison of means was performed using Student's *t*-test or analysis of variance and the Newman-Keuls test. Comparison of medians was performed using the Mann-Whitney *U* test or the Kruskal-Wallis test for multiple comparisons. Comparison of proportions was performed using Fisher's exact method with the Bonferroni correction when appropriate. Using logistic regression and all variables known at admission to the ICU, we determined variables associated with mortality at 90 days and calculated odds ratios (ORs) and their 95% confidence interval (CIs). Collinearity between variables was considered when *r* \>0.60 (Spearman's matrix correlation coefficient). Calibration of the model was assessed using the Hosmer-Lemeshow test, and discrimination was evaluated using the c-statistic. This model enabled us to calculate the probability of death at 90 days. Then we conducted a multivariate analysis including all significant variables in the model (age, body mass index (BMI), SAPS II score, SOFA score, McCabe score and cause of ICU admission) and by forcing the main variables of blood glucose metrics (severe and moderate hypoglycemia, number of hypoglycemic events (any type, 0 to 2 vs. ≥3), mean blood glucose level, blood glucose CV and type of blood glucose control (conventional vs. computerized)) into the model.

To reduce the effects of confounding, matched populations of patients without hypoglycemia and patients with moderate or severe hypoglycemia were created using propensity score matching. The propensity model was constructed to match pairs of patients without hypoglycemia and hypoglycemic patients using a multivariable logistic model and a greedy matching algorithm with a 1:1 (moderate hypoglycemia) or 2:1 (severe hypoglycemia, multiple hypoglycemic events) ratio and a caliper width of 10^−5^ digit with no replacement. Propensity score matching is one of the propensity score methods used to mimic some of the characteristics of a randomized controlled trial \[[@CR26]\]. Applied to the context of our observational study on hypoglycemic events, it consists of forming matched sets of hypoglycemic and non-hypoglycemic patients who share a similar value of the propensity score. In greedy matching within a specified caliper distance, a hypoglycemic patient is first selected at random; the patient without hypoglycemia whose propensity score is closest to that of this randomly selected hypoglycemic patient (with the further restriction that the absolute difference in the propensity scores of matched patients must be below the caliper distance) is chosen for matching to this hypoglycemic patient. This process is called greedy because at each step in the process, the nearest patient without hypoglycemia is selected for matching to the given hypoglycemic patient, even if that patient without hypoglycemia would better serve as a match for a subsequent hypoglycemic patient. This nearest patient without hypoglycemia is then no longer available for a new match with another hypoglycemic patient (no replacement). If no patients without hypoglycemia had propensity scores that lay within the specified caliper distance of the propensity score of the hypoglycemic patient, this unmatched hypoglycemic patient would then be excluded from the matching process. All variables available at admission were included in the matching model. We discarded from the analysis patients without hypoglycemia and hypoglycemic patients for whom no paired match was found. After matching, absolute standardized differences (ASD) were calculated to assess the similarity in preoperative patient characteristics and expressed as a percentage. An ASD \>10% was considered to represent a meaningful difference \[[@CR27]\]. In order to estimate the association of hypoglycemia and mortality in predefined population subgroups, the same analysis was then conducted in diabetic and non-diabetic patients and in the two groups (conventional vs. computerized blood glucose control).

All *P*-values were two-tailed, and a *P* value \<0.05 was considered significant. Statistical analysis was performed using NCSS 7.0 statistical software (NCSS, Kaysville, UT, USA) and R 3.1.1 software (<http://www.cran.r-project.org/>; The Comprehensive R Archive Network).

Results {#Sec8}
=======

Among the 2,684 randomized patients, 1,351 were assigned to computerized and 1,333 to conventional blood glucose control. Thirty-six patients were discarded from any analysis, thirty-five of whom withdrew consent and one who was included twice. Among the 2,648 remaining patients, 47 were discarded because important data concerning blood glucose measurement were lacking. Thus, 2,601 patients were analyzed (Figure [1](#Fig1){ref-type="fig"}).Figure 1**Flowchart of the study.**

Hypoglycemia (\<3.3 mmol/L) occurred in 1,127 patients (43%; 95% CI, 41% to 45%). The density of hypoglycemia was 0.30 events per day of insulin therapy and 0.15 events per day in the ICU. Severe hypoglycemia (\<2.2 mmol/L) occurred in 253 patients (10%; 95% CI, 9% to 11%). The density of severe hypoglycemia was 0.037 events per day of insulin therapy and 0.020 events per day in the ICU. Moderate hypoglycemia (2.2 to 3.3 mmol/L) occurred in 874 patients (34%; 95% CI, 32% to 35%). The density of moderate hypoglycemia was 0.26 events per day of insulin therapy and 0.13 events per day in the ICU. Figure [2](#Fig2){ref-type="fig"} shows the distribution of the number of hypoglycemic events per patient (severe, moderate, any type). Multiple hypoglycemic events (any type, n ≥3) occurred in 482 patients (19%; 95% CI, 17% to 20%), and their 90-day mortality was significantly increased compared with patients with fewer hypoglycemic events (51% vs. 29%; *P* \<0.001). Blood glucose variability was available in 2,507 patients. Moderate blood glucose variability (CV, 0.20 to 0.39) occurred in 1,447 patients (56%; 95% CI, 54% to 58%), and severe blood glucose variability (CV, ≥0.40) occurred in 238 patients (9%; 95% CI, 8% to 10%). The 90-day mortality was higher in patients with moderate or severe blood glucose variability compared with controls (respectively: 36% vs. 24%, *P* \<0.001; 42 vs. 24%, *P* \<0.001). There was no significant difference in 90-day mortality between moderate and severe blood glucose variability (*P* =0.21).Figure 2**Distribution of the number of hypoglycemic events per patient. (A)** Severe (\<2.2 mmol/L). **(B)** Moderate (2.2 to 3.3 mmol/L). **(C)** Any type (\<3.3 mmol/L).

Patients were divided into three groups: no hypoglycemia (n =1,474), moderate hypoglycemia (n =874) and severe hypoglycemia (n =253) (Figure [1](#Fig1){ref-type="fig"}). The main characteristics of patients in these three groups are shown in Table [1](#Tab1){ref-type="table"}. Patients with moderate or severe hypoglycemia had worse outcomes (Table [1](#Tab1){ref-type="table"}). However, they had more severe illness, as shown by their higher SAPS II and SOFA scores. They had more underlying diabetes and were more frequently mechanically ventilated, on vasopressor therapy or on renal replacement therapy (Table [1](#Tab1){ref-type="table"}). Blood glucose data are shown in Table [2](#Tab2){ref-type="table"}. Patients with moderate or severe hypoglycemia had higher blood glucose variability (SD and CV) and lower mean blood glucose levels (Table [2](#Tab2){ref-type="table"}). Comparable results were noted when considering patients with multiple hypoglycemic events (Table [1](#Tab1){ref-type="table"}).Table 1**Baseline characteristics and outcome of the study patients** ^**a**^**VariablesNo hypoglycemiaModerate hypoglycemiaSevere hypoglycemiaMultiple hypoglycemic events(n =1,474)(n =874)(n =253)(n =482)**Age, yr61 (17)63 (16)62 (15)63 (15)Male sex, n (%)963/1,474 (65)553/874 (63)163/253 (64)320/482 (65)Weight, kg80 (21)75 (18)^b^74 (20)^b^74 (18)^b^Body mass index, kg/m^2^27.5 (6.7)26.2 (5.9)^b^25.6 (6.1)^b^25.9 (6.0)SAPS II score46 (34 to 61)52 (40 to 67)^b^59 (46 to 74)^bc^65 (55 to 75)^b^SOFA score7 (4 to 10)8 (5 to 11)^b^10 (7 to 13)^bc^10 (7 to 12)^b^McCabe score1 (1 to 2)1 (1 to 2)1 (1 to 2)1 (1 to 2)Type of patientMedical872/1,474 (59)161/874 (60)161/253 (64)281/482 (60)Scheduled surgery457/1,474 (31)75/874 (29)75/253 (30)158/482 (30)Emergency surgery145/1,474 (10)17/874 (11)17/253 (7)53/482 (10)History of diabetes mellitus, n (%)266/1,474 (18)189/874 (22)70/253 (28)^b^131/482 (27)Type 1 diabetes, n (%)38/1,474 (3)32/874 (4)14/253 (6)22/481 (5)Type 2 diabetes, n (%)228/1,474 (15)157/874 (18)55/253 (22)108/481 (22)Not determinedPrevious treatment118/1,474 (5)21/873 (8)21/253 (8)35/482 (7)Insulin, n (%)114/1,474 (5)18/873 (7)18/253 (7)28/482 (6)Antidiabetic drugs, n (%)Plasma creatinine, μmol/L133 (140)150 (133)166 (158)^b^169 (147)^b^Initial treatment in the ICUMechanical ventilation1,273/1,430 (89)803/873 (92)240/253 (95)^b^453/482 (94)^b^Catecholamines708/1,428 (50)533/253 (61)^b^195/253 (77)^bc^353/482 (73)Renal replacement therapy119/1,428 (8)123/253 (14)^b^54/253 (21)^bc^96/482 (20)^b^Antibiotics924/1,428 (65)597/253 (68)180/253 (71)351/482 (73)Blood glucose controlConventional900/1,474 (61)305/874 (35)^b^79/253 (31)^b^126/482 (26)^b^Computerized574/1,474 (39)569/874 (65)^b^174/253 (69)^b^356/482 (74)^b^Treatment-free daysMechanical ventilation21 (0 to 26)14 (0 to 23)^b^0 (0 to 18)^bc^1 (0 to 18)^b^Catecholamines26 (17 to 28)23 (0 to 27)^b^15 (0 to 24)^bc^18 (0 to 25)^b^Renal replacement therapy28 (21 to 28)28 (0 to 28)^b^15 (0 to 28)^bc^24 (0 to 28)^b^ICU-free days20 (0 to 25)12 (0 to 12)^b^0 (0 to 17)^bc^0 (0 to 117)^b^MortalityDay 28315/1,474 (21)222/874 (25)^b^100/253 (39)^bc^162/482 (34)^b^Day 90407/1,474 (28)315/874 (36)^b^137/253 (54)^bc^248/482 (51)^ba^Data are expressed as mean (SD), median (25th to 75th interquartile range), and number (%). ICU, Intensive care unit; SAPS II, Simplified Acute Physiology Score II, on which scores can range from 0 to 156, with higher scores indicating more severe illness; SOFA, Sequential Organ Failure Assessment, on which scores can range from 0 to 24 with higher scores indicating more severe illness. ^b^ *P* \<0.05 vs. no hypoglycemia group; ^c^ *P* \<0.05 vs. moderate hypoglycemia group (comparison was performed only for severe hypoglycemia group).Table 2**Blood glucose metrics** ^**a**^**VariablesNo hypoglycemiaModerate hypoglycemiaSevere hypoglycemiaMultiple hypoglycemic events(n =1,474)(n =874)(n =253)(n =482)**Initial blood glucose, mmol/L8.9 (4.0)9.6 (4.6)^b^9.8 (5.5)^b^9.7 (4.2)^b^Mean morning blood glucose, mmol/L7.2 (2.3)6.8 (1.6)^b^6.8 (1.8)^b^6.7 (1.8)^b^Mean blood glucose, mmol/L7.2 (1.7)6.7 (1.2)^b^6.8 (1.5)^b^6.6 (1.2)^b^Maximum blood glucose, mmol/L11.3 (1.4)12.8 (4.1)^b^14.6 (5.1)^bc^14.2 (4.9)^b^Minimum Blood glucose, mmol/L4.6 (1.4)2.9 (0.3)1.7 (0.4)2.2 (0.6)Blood glucose standard deviation, mmol/L1.5 (1.0)2.0 (1.0)^b^2.4 (1.3)^bc^2.2 (1.1)^b^Blood glucose CV0.20 (0.15 to 0.26)0.27 (0.22 to 0.34)^b^0.32 (0.25 to 0.39)^bc^0.31 (0.25 to 0.38)^b^Blood glucose CV \>0.20715/1,428 (50%)735/873 (84%)^b^235/253 (93%)^bc^452/479 (94%)^b^Total insulin dose, IU121 (38 to 344)348 (123 to 801)^b^442 (129 to 986)^b^534 (201 to 1109)^b^Daily insulin dose, IU/day19 (4 to 41)34 (15 to 58)^b^35 (17 to 59)^b^38 (20 to 61)^b^Days with insulin5 (3 to 11)9 (4 to 17)^b^10 (5 to 20)^bc^12 (6 to 22)^b^Number of blood glucose measurements28 (16 to 56)44 (24 to 80)^b^52 (28 to 104)^bc^50 (32 to 108)^b^Number of moderate hypoglycemia2 (1 to 3)3 (1 to 6)4 (3 to 6)Number of severe hypoglycemia----1 (1 to 2)0 (0 to 1)Number of hypoglycemic events (any type)--2 (1 to 3)5 (3 to 8)4 (3 to 7)Hypoglycemic events (any type) ≥3--286 (33%)197 (77%)482 (100%)^a^Data are expressed as mean (standard deviation), median (25th to 75th interquartile range) and number (%). CV, Coefficient of variation. ^b^ *P* \<0.05 vs. no hypoglycemia group; ^c^ *P* \<0.05 vs. moderate hypoglycemia group (only for severe hypoglycemia group). The number of hypoglycemic events and the minimum blood glucose were not tested for statistical significance.

In the multivariable model, six variables were significantly associated with 90-day mortality: age, BMI, SAPS II score, SOFA score, McCabe score and the cause of ICU admission. The discrimination of the model was appropriate (c-statistic =0.745) as well as its calibration (Hosmer-Lemeshow test, χ^2^ =10.12, *P* =0.34). When added to this model, severe hypoglycemia, multiple hypoglycemic events and mean blood glucose level variables were significantly associated with 90-day mortality, in contrast to moderate hypoglycemia and blood glucose CV (Table [3](#Tab3){ref-type="table"}). We next performed a sensitivity analysis by excluding patients allocated to computerized blood glucose control and the variables severe hypoglycemia (OR =2.08; 95% CI, 1.12 to 3.86; *P* =0.02) and mean blood glucose level (OR =1.10; 95% CI, 1.00 to 1.21; *P* =0.045) remained significantly associated with 90-day mortality, whereas the variables moderate hypoglycemia (OR =1.34; 95% CI, 0.94 to 1.91; *P* =0.11) and multiple hypoglycemic events (OR =1.42; 95% CI, 0.85 to 2.37; *P* =0.18) were not.Table 3**Multivariable analysis of variables associated with 90-day mortality** ^**a**^ **(n =2,312)VariablesOdds ratio (95% CI)*P*** **-value**Age (per 1 yr)1.024 (1.017 to 1.031)\<0.001Body mass index (per 1 kg/m^2^)0.979 (0.963 to 0.995)0.008SAPS II score (per 1 point)1.019 (1.012 to 1.025)\<0.001SOFA score (per 1 point)1.086 (1.053 to 1.120)\<0.001McCabe score (per 1 point)1.587 (1.357 to 1.885)\<0.001Type of patientMedical1--Scheduled surgical0.663 (0.532 to 0.827)\<0.001Emergency surgical0.460 (0.321 to 0.657)\<0.001Moderate hypoglycemia1.114 (0.865 to 1.436)0.40Severe hypoglycemia1.571 (1.055 to 2.339)0.03Number of hypoglycemic events ≥31.834 (1.361 to 2.471)\<0.001Mean blood glucose (per 1 mmol/L)1.086 (1.010 to 1.168)0.03Blood glucose CV \<0.201--Blood glucose CV 0.20 to 0.391.155 (0.906 to 1.472)0.24Blood glucose CV ≥0.401.041 (0.698 to 1.552)0.84Computerized blood glucose control0.786 (0.639 to 0.958)0.02^a^CV, Coefficient of variation; OR, Odds ratio; CI, Confidence interval; c-index =0.757; SAPS, Simplified Acute Physiology Score; SOFA, Sequential Organ Failure Assessment.

Using multivariable matching, we matched each patient with severe hypoglycemia with two patients without hypoglycemia, each patient with moderate hypoglycemia with one patient without hypoglycemia, and each patient with multiple hypoglycemic events with two patients without hypoglycemia. The proportion of discarded patients were 27% in the moderate hypoglycemia group, 21% in the severe hypoglycemia and 51% in the multiple hypoglycemic events groups. After matching, the highest ASD was 5.9%. Table [4](#Tab4){ref-type="table"} shows the comparison between these matched groups of patients. Although the matching process provided two groups that were comparable for severity, patients with moderate or severe hypoglycemia and those with multiple hypoglycemic events had a poorer prognosis, as shown by a higher 90-day mortality and decreased number of treatment-free days (Table [4](#Tab4){ref-type="table"}).Table 4**Comparison of outcome and blood glucose metrics in matched groups** ^**a**^**Matching for moderate hypoglycemiaMatching for severe hypoglycemiaVariablesNo hypoglycemiaModerate hypoglycemia*P*** **-valueNo hypoglycemiaSevere hypoglycemia*P*** **-value(n =640)(n =640)(n =366)(n =199)**Probability of death0.28 (0.19)0.28 (0.18)0.660.32 (0.19)0.35 (0.19)0.12OutcomesRRT-free days28 (21 to 28)28 (7 to 28)0.0628 (0 to 28)24 (0 to 28)\<0.001Catecholamine-free days25 (17 to 27)24 (2 to 27)\<0.00124 (0 to 26)18 (0 to 25)\<0.001Mechanical ventilation to free days20 (0 to 25)15 (0 to 23)\<0.00117 (0 to 24)18 (0 to 25)\<0.001ICU-free days19 (0 to 24)13 (0 to 22)\<0.00117 (0 to 24)0 (0 to 28)\<0.001Mortality 28 days137 (21%)151 (24%)0.38102 (28%)75 (38%)0.017Mortality 90 days176 (27%)213 (33%)0.029131 (35%)106 (53%)\<0.001Blood glucose metricsMean blood glucose7.2 (1.6)6.6 (1.1)\<0.0017.3 (1.6)6.8 (1.5)\<0.001Blood glucose CV0.21 (0.09)0.28 (0.09)\<0.0010.22 (0.09)0.33 (0.12)\<0.001Insulin dose (IU/day)22 (6 to 43)35 (5 to 59)\<0.00123 (7 to 41)35 (19 to 56)\<0.001**Matching for multiple hypoglycemic eventsVariablesNo hypoglycemiaMultiple hypoglycemic*P*** **-value(n =445)(n =234)**Probability of death0.32 (0.20)0.32 (0.19)0.81OutcomesRRT-free days28 (0 to 28)28 (0 to 28)0.06Catecholamine-free days24 (0 to 26)19 (0 to 25)0.001Mechanical ventilation to free days18 (0 to 24)5 (0 to 18)\<0.001ICU-free days17 (0 to 24)1 (0 to 17)\<0.001Mortality 28 days115 (26%)64 (27%)0.71Mortality 90 days141 (32%)108 (46%)\<0.001Blood glucose metricsMean blood glucose7.0 (1.5)6.7 (1.0)\<0.001Blood glucose CV0.24 (0.10)0.31 (0.09)\<0.001Insuline dose (IU/day)26 (8 to 49)41 (22 to 63)\<0.001^a^Data are expressed as mean (standard deviation), median (25th to 75th interquartile range) and number (%). ICU, Intensive care unit; RRT, Renal replacement therapy; CV, Coefficient of variation.

The association of severe and moderate hypoglycemia and multiple hypoglycemic events with 90-day mortality was not different among the prespecified subgroup analyses (non-diabetic patients, computerized decision support systems and conventional glucose control), except for patients with diabetes (Figure [3](#Fig3){ref-type="fig"}).Figure 3**Subgroup analysis.** Odds ratio (OR) and 95% confidence interval (CI) for death at 90 days associated with moderate (filled squares) or severe (filled circles) hypoglycemia or multiple (n ≥3) hypoglycemic (filled triangles) events in the total population and in matched subgroups according to treatment assignment (conventional vs. computerized decision support system (CDSS)) and diabetes status (diabetic vs. non-diabetic). Matching was performed using propensity score and a ratio of 2:1 for severe hypoglycemia and 1:1 for moderate hypoglycemia and multiple hypoglycemic events. The size of symbols is related to the number of patients (N) retained in the matching process.

Discussion {#Sec9}
==========

In this study, in a large cohort of ICU patients and using two different statistical approaches, we observed that both severe hypoglycemia and multiple hypoglycemic events were associated with increased risk of death. Blood glucose CV was not associated with mortality.

From methodological and clinical points of view, we considered that it was important to perform the best possible adjustment for severity, but using only variables observed at ICU admission. In contrast to some previous researchers \[[@CR11],[@CR28]\], we did not include any post-ICU admission variable, such as the ICU length of stay, because if hypoglycemia has intrinsic deleterious effects, it should have been able to also impact these variables. We observed that, indeed, hypoglycemia was associated with increased ICU length of stay and use of mechanical ventilation, catecholamines and renal replacement therapy, even when we adjusted for initial severity (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Although many researchers have found an association between hypoglycemia and mortality \[[@CR11]-[@CR17],[@CR28]\], others have not \[[@CR14],[@CR29]\]. Using two different statistical approaches, our study confirms this association between hypoglycemia and mortality, at least when considering patients with severe hypoglycemia and multiple hypoglycemic events (Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). Matching using propensity score is increasingly reported in the medical literature \[[@CR30]\] and has been shown to perform better than multivariable logistic regression in many situations \[[@CR19]\]. In our present study, these two approaches lead to consistent estimates of increased 90-day mortality associated with hypoglycemia. The magnitude of the increased risk of death observed in our study is also consistent with previous reports \[[@CR11],[@CR16],[@CR17],[@CR25],[@CR31]\].

There are three recognized domains of blood glucose metrics---mean blood glucose level, hypoglycemia and blood glucose variability---and all of them have been suspected to be linked to mortality in critically ill patients \[[@CR13],[@CR20]\]. An important difficulty arises because all these variables are associated with initial severity in ICU patients and are significantly correlated one with the other, mathematically and probably clinically. Moreover, diabetic status is thought to modulate these relationships \[[@CR28]\], and the dose of insulin may also be considered as a fourth domain because a high dose of insulin may indicate a high degree of insulin resistance (which is also linked to illness severity) \[[@CR32]\] and/or may be associated with non-glucose-related therapeutic effects of insulin \[[@CR33]\]. Consequently, there is some debate concerning the respective roles of the different main domains of blood glucose metrics. Our study provides some evidence that blood glucose variability is less important than hypoglycemia. First, we did not observe a dose--response relationship for 90-day mortality with CV, using either a crude or adjusted analysis. Second, after adjusting for initial severity, blood glucose CV was not significantly associated with mortality (Table [3](#Tab3){ref-type="table"}).

Although we performed the best adjustment possible using variables associated with initial severity, a causal relationship between hypoglycemia and mortality cannot be proven in such an observational study \[[@CR34]\]. Nevertheless, some arguments are in favor of the existence of a causal relationship in an observational study, at least partially \[[@CR35]\]. Among them (strength and consistency of the association, specificity, temporal relationship, plausibility, coherence, experiment and analogy), the Normoglycemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR) investigators have already evidenced specificity because the association was strongest for death from distributive shock \[[@CR13]\]. As previously observed \[[@CR11],[@CR13],[@CR14],[@CR17],[@CR28],[@CR31]\], we observed a dose--response relationship as severe hypoglycemia was associated with higher rates of death than was moderate hypoglycemia or the occurrence of multiple hypoglycemic events. The fact that blood glucose variability did not seem to be associated with mortality is an important point, which reinforces the hypothesis that hypoglycemia (at least severe and/or multiple) is deleterious. It may be also an argument against the hypothesis that the harm of hypoglycemia comes instead from its rapid correction leading to rebound hyperglycemia \[[@CR13]\], because this situation is expected to increase blood glucose variability. As previously reported \[[@CR28]\], our study also confirms that patients with diabetes may behave differently (Figure [3](#Fig3){ref-type="fig"}), but the small sample size of this group precludes definite conclusion.

Our study may enable us to reanalyze our previous published trial on tight blood glucose control, which was characterized by a significant decrease in mean blood glucose with a significant increase in hypoglycemia rate without any impact on mortality \[[@CR7]\]. It should be pointed out that such a discrepancy between mortality rate (unchanged) and hypoglycemia rate (increased) was also observed in all previous major trials \[[@CR4]-[@CR6]\], except one \[[@CR8]\], excluding the first trial performed during an era without any blood glucose control performed in the control group \[[@CR3]\]. This discrepancy was also confirmed by a more recent meta-analysis \[[@CR36]\]. Considering that hypoglycemia may be both a marker of severity and a deleterious event, two different hypotheses can be evoked in our trial \[[@CR7]\]. First, the benefit of the improvement in blood glucose control may have been masked by the deleterious effects of hypoglycemia. Second, if hypoglycemia is only a marker of illness severity, tight blood glucose may have induced iatrogenic hypoglycemia, which may not be associated with a higher mortality rate. It is not possible to draw definite conclusions, and the two hypotheses may not be exclusive. Anyway, because many arguments suggest that hypoglycemia, at least severe and/or multiple episodes, may be, at least partially, causally associated with mortality, clinicians and caregivers should continue to try to prevent, detect and treat hypoglycemia, particularly when it is severe and/or episodes are repeated. It should be pointed out that we were not able to differentiate iatrogenic (related to insulin administration) and spontaneous hypoglycemic events, whereas the last one is thought to be more strongly associated with mortality, but with possible less of a causal link \[[@CR37]\]. Our study provides additional arguments to reduce or suppress hypoglycemic events induced by insulin protocols. Indeed, although most recommendations or guidelines have recently advocated for a higher glucose range target in the ICU based on recent meta-analyses showing a strong association between the glucose range targeted in insulin protocols and the risk for hypoglycemia, our study should lead to optimization of the quality of glycemic control by improving the algorithms embedded in glucose controllers that calculate insulin rates to avoid hypoglycemia, especially in situations where the patient is exposed to variable insulin resistance, rather than by simply increasing the blood glucose target. In other words, minimizing occurrence and recurrence of hypoglycemic events seems more clinically relevant than choosing a high blood glucose target. It has already been demonstrated that an advanced protocol may both decrease the average blood glucose level and reduce the incidence of hypoglycemic events \[[@CR38]\]. Further studies are required to develop high-performance glucose controllers in the ICU and to determine the best compromise between individualized blood glucose targets and the risk of hypoglycemia. Finally, whatever the causal link between hypoglycemia and mortality, prevention of hypoglycemic events is needed in the ICU because the occurrence of severe hypoglycemia is *a priori* associated with an increase in nurse workload (*via* additional time required for administering glucose in cases of severe hypoglycemia, which subsequently increases the risk of hyperglycemic rebound and creates a need for more frequent blood glucose monitoring after the hypoglycemic event (in the absence of continuous blood glucose monitoring system)).

In the same manner, our database did not enable us to assess the attributable mortality by incorporating the evolution in severity of illness during the ICU stay and using causal inference methods \[[@CR39]\].

The strengths of our study are its size and its prospective and multicentric nature, with a high proportion of patients treated with insulin (98%), a low mean blood glucose level (7.2 mmol/L) within the actual recommended target \[[@CR40]\] and a high proportion of patients still in the ICU on the third day (94%). The initial high severity of our patients is shown by the high severity scores (median SAPS II =51, median SOFA =8) and the high mortality rate (33%) \[[@CR7]\].

Our study has several limitations. First, sampling of blood glucose was intermittent, and thus it is possible that some patients had undetected hypoglycemia. Second is the absence of data regarding nutritional intake. Third, the fact that our cohort comprises two randomized groups with different methods of blood control may also be considered as a limitation. Nevertheless, the use of a computerized decision support system seemed not to have interfered with our results, except for the role of moderate hypoglycemia because the association between moderate hypoglycemia and mortality was different between the two randomized groups (Figure [3](#Fig3){ref-type="fig"}). Fourth, the diabetic status of our patients was not precisely determined using measurement of blood glucose after provoked hyperglycemia or glycated hemoglobin measurement, and thus we did not identify patients with prediabetic or occult diabetic status. In ICU patients, hyperglycemia seems not to be associated with significant increase in mortality in the subgroup of patients with premorbid hyperglycemia \[[@CR41]\], but information is lacking with regard to hypoglycemia. Fifth, in ICU patients, severity of hypoglycemic events is usually defined by a biological threshold without a possibility to precisely record clinical signs, and this should also be considered as a limitation, as well as the lack of recording of the duration of the hypoglycemic events and the possible associated rebound in blood glucose levels. Sixth, we did not test all possible metrics of blood glucose variability, but no significant difference has been shown between them \[[@CR20]\]. Last, because we included only adult patients, our results may not apply to a pediatric population \[[@CR42]\].

Conclusion {#Sec10}
==========

Using two different but concordant statistical approaches in a large cohort of ICU patients, we observed that severe hypoglycemia and multiple hypoglycemic events were associated with increased risk of death at 90 days. In contrast, blood glucose variability was not associated with 90-day mortality.

Key messages {#Sec11}
============

Severe hypoglycemia (\<2.2 mmom/L) is associated with increased risk of death at 90 days in critically ill patients.Multiple hypoglycemic episodes (at least three of any type of hypoglycemia, severe or moderate (2.2 to 3.3 mmol/L)) are associated with increased risk of death at 90 days in critically ill patients.

ASD

:   Absolute standardized difference

BMI

:   Body mass index

CDSS

:   Computerized decision support system

CI

:   Confidence interval

CV

:   Coefficient of variation

ICU

:   Intensive care unit

OR

:   Odds ratio

SAPS II

:   Simplified Acute Physiology Score II

SD

:   Standard deviation

SOFA

:   Sequential Organ Failure Assessment
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